The rationale for developing a combined eniluracil/5-FU formulation oral dosing form is to simplify treatment with these agents , which has been performed using separate dosing forms , and decrease the probability of severe toxicity and/or suboptimal therapeutic results caused by inadvertently high or conversely insufficient 5-FU dosing .
